The FDA Has Approved New Trials for the Use of Ecstasy for PTSD Patients
![](https://drmikedow.com/wp-content/uploads/2017/06/94ccb8824cc2a4acd427809d5a34a917.jpg)
The Food and Drug Administration (FDA) gave the go-ahead Tuesday for large-scale clinical trials of MDMA for the treatment of posttraumatic stress disorder.
MDMA — better known as Ecstasy — will be part of phase 3 clinical trials, a final step before the party drug is potentially approved as a prescription drug for the treatment of PTSD, the New York Times reports. If approved, Ecstasy could become a prescription drug by 2021.